Dubai: Globalpharma, the UAE’s leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, has announced the inauguration of the Ministry of Health & Prevention (MOHAP) approved first herbal manufacturing line to produce MG21 in collaboration with Al Fujairah Healing.
MG21 is an herbal anti-inflammatory medicine consisting of a composition of herbs like Myrrh and Costus, used for the treatment and prevention of various types of infections ranging from respiratory infections, indigestion, skin infections, headaches, and diabetic conditions.
Under the patronage of His Royal Highness Sheikh Hamad bin Mohammed Al Sharqi, Supreme Council Member and Ruler of Fujairah, Al Fujairah Healing Company selected Globalpharma to develop, sell, market, promote and distribute MG21 across the Middle East.
H.E Dr. Amin Hussain Al Ameeri, Asst. Undersecretary of the Health Regulation Sector at MOHAP inaugurated the dedicated manufacturing unit with the commencement of the commercial production of MG21.
The facility at the Globalpharma premises in Dubai Investments Park (DIP) with fully separated facilities for manufacturing herbal products, built to the highest standards as per cGMP standards is estimated to yield an annual production capacity of around half million capsules.
Globalpharma has implemented efficient control method to ensure the product meets stringent quality pharma regulations and marks the horizontal integration of the plant and expansion into a new dosage form.
Mohammed Saeed Al Raqbani, General Manager of Dubai Investment Industries said: “Globalpharma aims to progress into a globally attractive and technologically driven integrated healthcare enterprise, focussed on continually innovating and adapting to deliver the best in healthcare. We are pleased to add the MG21 herbal medicine to our existing line-up of medicines and to locally produce it at our fully GMP compliant facility. Embarking on this exciting journey with Al Fujairah Healing Company, we believe that this herbal medicine will not only become a popular product with consumers, but also help strengthen the UAE’s position as a leader in pharmaceuticals in the region.”
Basem AlBarahmeh, General Manager of Globalpharma said: “Globalpharma has already signed a distribution agreement with Alphamed, one of the leading local suppliers in the country, with the aim of securing availability of MG21 in the majority of pharmacies before the end of this year”
-Ends-
About Globalpharma:
Globalpharma is a wholly owned subsidiary of Dubai Investments. Established in 1998 and headquartered in Dubai Investments Park, Globalpharma grew to become a market leader in certain generic medicines with a strong regional footprint. Globalpharma manufactures and markets pharmaceutical products in more than 14 countries across the GCC, Middle East and neighbouring markets. Globalpharma manufactures and commercializes pharmaceutical products under CGMP (current good manufacturing practice) conditions including antibiotics, cardiovascular, anti-ulcerants, analgesic, NSAIDs (Nonsteroidal anti-inflammatory drugs), food supplements, vitamins, anti-diabetics, respiratory products, and antihistamine formulations.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
